

1 **Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients**

2

3 **Natalia Ruetalo¹, Ramona Businger¹, Karina Althaus², Simon Fink³, Felix Ruoff³**

4 **Klaus Hamprecht¹, Bertram Flehmig⁴, Tamam Bakchoul², Markus F. Templin³,**

5 **Michael Schindler^{1*}**

6

7 ¹ Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital

8 Tübingen, Tübingen, Germany

9 ² Institute for Transfusion Medicine, University Hospital Tübingen, Tübingen, Germany

10 ³ NMI, Reutlingen, Germany

11 ⁴ Mediagnost GmbH, Reutlingen, Germany

12

13

14

15

16

17

18

19 *Correspondence should be addressed to:

20 Michael Schindler, michael.schindler@med.uni-tuebingen.de

21

22

23

24

25 **Abstract**

26 The majority of infections with SARS-CoV-2 are asymptomatic or mild without the
27 necessity of hospitalization. It is of importance to reveal if these patients develop an
28 antibody response against SARS-CoV-2 and to define which antibodies confer virus
29 neutralization. We conducted a comprehensive serological survey of 49 patients with a
30 mild course of disease and quantified neutralizing antibody responses against a clinical
31 SARS-CoV-2 isolate employing human cells as targets.

32 Four patients (8%), even though symptomatic, did not develop antibodies against SARS-
33 CoV-2 and two other patients (4%) were only positive in one of the six serological assays
34 employed. For the remainder, antibody response against the S-protein correlated with
35 serum neutralization whereas antibodies against the nucleocapsid were poor predictors
36 of virus neutralization. Regarding neutralization, only six patients (12%) could be
37 classified as highly neutralizers. Furthermore, sera from several individuals with fairly
38 high antibody levels had only poor neutralizing activity. In addition, employing a novel
39 serological Western blot system to characterize antibody responses against seasonal
40 coronaviruses, we found that antibodies against the seasonal coronavirus 229E might
41 contribute to SARS-CoV-2 neutralization.

42 Altogether, we show that there is a wide breadth of antibody responses against SARS-
43 CoV-2 in patients that differentially correlate with virus neutralization. This highlights the
44 difficulty to define reliable surrogate markers for immunity against SARS-CoV-2.

45

46

47

48

49 **Introduction**

50 The most recent emerging virus outbreak happened in China in December 2019 caused
51 by SARS (severe acute respiratory syndrome) coronavirus-2 (SARS-CoV-2) (1), leading
52 to a pandemic, as defined by the WHO in March 2020 (2, 3). Infections with SARS-CoV-
53 2 can cause the so-called disease COVID-19 (Coronavirus disease 2019). 50% of all
54 COVID-19 cases range from asymptomatic to mild. 30% show moderate to pronounced
55 symptoms. 5-20% of patients are hospitalized due to critical course of infection with
56 severe lung complications and on average ~5% die, even though there is high variation
57 dependent on the country (4). Recent data from a multicentric cohort of 10021
58 hospitalized COVID-19 patients, showed an in-hospital mortality of 73% in mechanically
59 ventilated patients requiring dialysis, and of 53% of invasively ventilated patients (5).
60 One critical determinant of illness is age, as mortality is highest in the elderly population
61 (1, 2, 4, 5). SARS-CoV-2 is currently spreading in an immune naive population and a
62 vaccine is not yet available, even though there are numerous candidates in the
63 advanced development pipeline (6). For an updated online resource refer to
64 <https://biorender.com/covid-vaccine-tracker>.

65 The pandemic is not only devastating in terms of the direct harm to human health
66 inflicted by the virus infection, but the continuous quarantine and lock-down
67 measurements have enormous negative impact on the socio-economical life of billions of
68 individuals (7). With the potential of achieving herd immunity as the virus spreads within
69 the population, numerous studies analyzing the prevalence of SARS-CoV-2-specific
70 antibodies in the population have been initiated (8-11).

71 Regardless of the prevalence of antibodies against SARS-CoV-2, one still poorly defined
72 determinant is what type of antibodies neutralize SARS-CoV-2 and hence potentially

73 confer protective immunity against the infection, even though very recent data using
74 Vero cells and pseudovirus systems suggest IgG against the receptor binding domain
75 play a role (12, 13). Besides, antibodies that bind to SARS-CoV-2 but do not result in
76 neutralization might enhance infection, a phenomenon called antibody-dependent
77 enhancement (ADE) (14, 15), which has not been investigated either. Finally, the role of
78 cross-protecting antibodies from seasonal coronaviruses is also discussed, but not yet
79 experimentally assessed (14).

80 To shed further light on the determinants of human serum to neutralize SARS-CoV-2 we
81 performed a comprehensive serological analysis of 49 individuals that were non-
82 hospitalized and range from an asymptomatic to a mild course of disease. We employed
83 several assays measuring SARS-CoV-2-specific IgGs against the S-protein, the S-
84 protein RBD, and the nucleocapsid. Furthermore, we assessed S-RBD specific IgM and
85 IgA and used a novel innovative throughput Western-blot system to detect IgGs against
86 SARS-CoV-2 and seasonal coronaviruses. Finally, all serological parameters were
87 associated with the ability of the 49 sera to neutralize the infection on human cells with a
88 clinical SARS-CoV-2 isolate.

89

90 **Results**

91 **The majority of patients develop SARS-CoV-2-specific antibodies**

92 For our serological survey, we recruited individuals coming to the Department of
93 Transfusion Medicine to donate blood for plasma therapy. All 49 patients included in this
94 study were non-hospitalized with asymptomatic to mild courses of disease, including
95 cough (69%), fever (59%), limb pain and headache (35%), diarrhea (10%), and loss of
96 taste (10%) (Supplementary Table 1). The age ranged from 19-66 years (median 40

97 years), gender was balanced (24 male, 25 female). The time from positive SARS-CoV-2
98 test to blood sampling was 14-64 days (median 45 days).

99 We employed several serological assays to detect antibodies against SARS-CoV-2
100 (Table 1 and Supplementary Table 1). IgG ELISAs against the S-protein (Euroimmune)
101 and S-protein RBD (Mediagnost), IgA and IgM against S-RBD (Mediagnost) as well as
102 an ECLIA detecting IgG against the viral nucleocapsid (NC, Roche). Furthermore, we
103 applied a throughput Western blot system (DigiWest) allowing detection of SARS-CoV-2
104 and seasonal coronavirus antibodies (16).

105 4/49 (8%) sera were negative in all serological assays employed to detect SARS-CoV-2-
106 specific antibodies, even though they were symptomatic showing two or more symptoms.
107 In addition, two more sera were only positive in one of the four assay systems to detect
108 IgGs against S or NC, which is the reason why we consider these sera also negative.
109 Apart from the robust IgG-response both against the S-protein (90%) and NC (80%),
110 development of S-specific IgM and IgA was less prominent, with 35 and 30% of positive
111 sera respectively (Supplementary Table 1).

112 In sum, even though 12% (6/49) of patients did not develop antibodies against SARS-
113 CoV-2, the vast majority (88%, 43/49) of individuals mount a robust SARS-CoV-2-
114 specific antibody response.

115

116 **Few patients develop high virus neutralizing titers (VNTs) after SARS-CoV-2** 117 **infection**

118 The majority of SARS-CoV-2 infected individuals seroconvert within 14 days (Guo et al.,
119 2020); however, it is less clear how potently sera from these patients neutralizes SARS-
120 CoV-2 (17). To test for virus neutralization we established two procedures using human

121 Caco-2 cells as targets (Fig. 1a). First, we infected cells with a SARS-CoV-2 strain
122 isolated from a throat swab of a patient showing a high viral load as determined by qRT-
123 PCR. This strain was designated SARS-CoV-2 200325_Tü1. Cells were co-incubated
124 with patient sera and virus in serial two-fold dilutions from 1:20 up to 1:2560. 48 hpi cells
125 were fixed with 80% acetone and immunofluorescence stained against SARS-CoV-2
126 antigens with a highly potent patient serum we retrieved from a hospitalized
127 convalescent donor. Cells were counter-stained with DAPI and infection rates quantified
128 via automated fluorescence-microscopy. For the second approach, we employed the
129 mNeonGreen expressing infectious SARS-CoV-2 clone [12]. Cells were treated and
130 infected exactly as explained for the SARS-CoV-2 Tü1 strain, but using slightly adjusted
131 dilutions of sera; 1:40 to 1:5120. 48 hpi cells were fixed with 2% PFA containing
132 Hoechst33342 as nuclear stain (Fig. 1b, representative sera examples of both
133 procedures). Infection rates of the corresponding serum dilutions were used to plot
134 sigmoidal inhibition curves and calculate the virus-neutralizing titer 50 (VNT_{50}) which is
135 the serum dilution inhibiting the half-maximal infection (Fig. 1c). The VNT_{50} values of the
136 sera obtained with the primary patient isolate correlated highly significantly with the titers
137 calculated when using the mNeonGreen-expressing infectious clone ($r=0.7349$; Fig.1d).
138 We only obtained slight discrepancies for highly potent sera that seemed to neutralize
139 SARS-CoV-2-mNG more efficiently than SARS-CoV-2-Tü1 at high dilutions. In both
140 assays, sera from four healthy donors and two consecutive sera from a hospitalized
141 convalescent patient were either completely negative for VNT as well as all serological
142 assays, or showed robust neutralization and SARS-CoV-2-specific antibodies (Table 1).
143 Patient sera were classified according to their neutralizing capacity (Fig. 1e) revealing
144 that only 12% (6/49) were highly potent neutralizers. 8% (4/49) of sera did not neutralize

145 SARS-CoV-2 at all *in vitro* and 24% (12/49) were poor neutralizers even though showing
146 robust signals in the different serological assays employed. Of note, using human Caco-
147 2 cells that express human Fc-receptors (18), we should be able to observe ADE.
148 However, none of the sera enhanced infection of SARS-CoV-2 at any dilution, arguing
149 against ADE, at least in our system. Hence, there is a large diversity in the ability of
150 patient sera to neutralize SARS-CoV-2 which is not always associated with the amount
151 of SARS-CoV-2-specific antibodies.

152

153 **VNT₅₀ is not associated with specific patient characteristics, apart from gender**

154 We next assessed potential associations of patient characteristics with serum
155 neutralization. Neither the sampling date 14-64 days (Fig. 2a) nor patient age (Fig. 2b)
156 correlated with serum neutralization. This indicates that seroconversion, as reported, is
157 achieved within 14 days in all patients and VNTs might not drop up to 64 days. On
158 average, titers were higher in males as compared to females (Fig. 2c). In detail, 3/4
159 individuals that did not neutralize at all were female but 5/6 highly potent neutralizers
160 were male (Supplementary Table 1). Furthermore, the average VNT₅₀ of men is double
161 as compared to women (613 vs 322; compare Fig. 2c). Of note, there was no association
162 of VNT₅₀ with the severity of disease (Fig. 2d), respectively amount of symptoms.

163

164 **SARS-CoV-2-specific IgG against the S-protein RBD indicate serum neutralization**

165 Next, we set out to define serological correlates of virus neutralization *in vitro*. Overall,
166 the neutralizing capacity of the sera correlated with the abundance of SARS-CoV-2
167 specific IgG against the S-protein ($r=0.6137$; Fig. 3a), with a slightly better r-value when
168 the IgG-measured were RBD-specific ($r=0.7198$; Fig. 3b). This indicates, as expected,

169 that antibodies against the RBD are involved in SARS-CoV-2-neutralization. Similarly,
170 RBD-specific IgA and IgM correlated with neutralization (Fig. 3c and Fig. 3d), even
171 though their abundance is highly diverse in the patient cohort (Supplementary Table 1).
172 In contrast, IgGs against the SARS-CoV-2-nucleocapsid measured by the Roche ECLIA
173 poorly correlated with serum neutralization ($r=0.3249$; Fig. 3d).
174 In conclusion, ELISAs or antibody tests, quantifying antibodies against the S-protein and
175 in particular the S-RBD correlate best with patient serum neutralization.

176

177 **Antibodies against seasonal coronavirus 229E correlate with serum neutralization** 178 **of SARS-CoV-2**

179 It is a matter of ongoing debate if antibodies against seasonal coronaviruses might
180 confer cross-protection against SARS-CoV-2. To get first insights into this question, we
181 took use of a quantitative throughput Western blot-based detection system identifying the
182 bulk of IgGs against a specific coronavirus (16). As expected and in line with our
183 previous data (Fig. 3a and 3b), IgG against SARS-CoV-2 correlated with VNT_{50}
184 ($r=0.6592$; Fig. 4a). Of note, IgG against the seasonal coronavirus 229E was also
185 associated with VNT_{50} ($r=0.4136$, $p=0.0017$; Fig. 4b), indicating that this class of
186 antibodies might support SARS-CoV-2 neutralization. Remarkably, this effect was
187 specific for 229E and neither observed for seasonal coronaviruses OC43 (Fig. 4c) nor
188 NL63 (Fig. 4d). In conclusion, even though based on correlation analyses, our data
189 indicates that a humoral immune response against the seasonal coronavirus 229E might
190 support SARS-CoV-2 neutralization.

191

192

193 Discussion

194 Recent studies assessed the development of virus-specific antibodies in various cohorts
195 of COVID-19 convalescent individuals (12, 13, 19-21). Overall, the data of the latter is in
196 accordance with ours, showing that the vast majority of individuals develop SARS-CoV-
197 2-specific antibodies. Furthermore, SARS-CoV-2-specific IgGs were more prevalent than
198 IgMs (20, 21), a finding that we confirm and extend to the abundance of SARS-CoV-2-
199 specific IgA. Using pseudovirus-based neutralization assays Robbiani et al. (20) also
200 report that there is a correlation between VNT_{50} and antibodies against the S-RBD.
201 Furthermore, males had significantly higher neutralizing activity than females, a finding
202 which is also supported by our data (Fig. 2c). We extend the aforementioned studies by
203 several aspects. First, for all our neutralization experiments we employed a fully
204 infectious clinical SARS-CoV-2-isolate on a human cell line. Second, we performed a
205 comprehensive comparison of several serological tests to delineate correlates of SARS-
206 CoV-2 neutralization. This revealed that NC-specific antibodies poorly correlate with
207 serum virus neutralization. In contrast, as supported by the findings of Robbiani et al.
208 (22) and Ju et al (23) RBD-specific IgGs correlate best with serum neutralization (Fig.
209 3b). In this context, it is noteworthy that S-RBD specific IgA and IgM also showed a high
210 degree of correlation with the VNT_{50} (Fig. 3c and 3d), indicating that these antibodies,
211 even though their abundance was highly diverse in our patient cohort, might contribute to
212 serum neutralization.

213 A phenomenon that is critically discussed is the potential enhancement of infection by
214 non-neutralizing antibodies (ADE) (14). For our VNT-assays, we are using human cells
215 expressing a diverse set of F_c -receptors, and directly assess the rate of infected cells by
216 immunofluorescence or reporter-gene expression. Hence, we should be able to detect

217 enhancement of infection by serum that is not or only poorly neutralizing and in higher
218 dilution ranges. However, in none of our 49 sera we observed ADE at any of the dilutions
219 tested, indicating that at least antibodies generated in the natural context of SARS-CoV-
220 2 infection do not contribute to severity of infection. This is in line with the absence of a
221 correlation between the number of symptoms and VNT_{50} in our patients (Fig. 2d). On the
222 other hand, our cohort is biased due to the fact that none of the patients was
223 hospitalized. Therefore, it will be important to analyze if ADE plays a potential role in
224 severe cases of COVID-19.

225 Up to now, it was elusive if antibodies against seasonal coronaviruses that are highly
226 prevalent within the human population play a role in SARS-CoV-2 neutralization. We
227 employed an innovative throughput Western blot system to concomitantly detect
228 antibodies specific against SARS-CoV-2 as well as the seasonal coronaviruses 229E,
229 OC43 and NL63 (16). In fact, 100% of individuals included in our study had antibodies
230 against the three seasonal coronaviruses with high diversity in relative numbers
231 (Supplementary Table 1). Correlating the latter with our VNT_{50} values revealed a
232 significant association of 229E-specific IgGs with the ability of patient sera to neutralize
233 SARS-CoV-2 infection (Fig. 4b). This effect was 229E-specific since none of the other
234 seasonal coronaviruses showed such an association (Fig. 4c and 4d). While it is clear
235 that 229E-specific IgGs are not sufficient to confer cross-protection against SARS-CoV-
236 2, our data imply, based on correlation analyses, that the prevalence of such antibodies
237 might assist in the neutralization of SARS-CoV-2. A hypothesis that is in line with the
238 observation that antibodies directed against the RBD of SARS or MERS alone are not
239 sufficient to inactivate SARS-CoV-2 (23). It will be highly interesting to analyze if the
240 epidemiology of seasonal coronaviruses is a determinant of COVID-19 severity, with the

241 implication that in areas with a high prevalence of antibodies against 229E mortality is
242 decreased.

243 Altogether, we here establish several correlates of SARS-CoV-2 neutralization by patient
244 serum using a relevant virus-neutralization test. Even though S-RBD-specific IgGs
245 correlate best with serum neutralization, it is clear that multiple factors contribute to a
246 potent neutralizing antibody response. This might include subclasses of S-specific
247 antibodies as for instance IgM and IgA as well as the antibody response elicited against
248 the seasonal coronavirus 229E. This makes it particularly difficult to define singular
249 serological correlates of immune protection as discussed in the context of COVID-19
250 “immunity passports”. Furthermore, such an approach neglects other potentially essential
251 factors of immune protection as for instance, T-cell mediated immunity (24, 25) and the
252 innate immune response (26).

253

254 **Author contributions**

255 NR, RB, and MS established the neutralization test and performed all experiments with
256 SARS-CoV-2; KA and TB provided patient samples and did the Euroimmune ELISA; BF
257 performed all ELISAs provided by Mediagnost; KH established, analyzed and supervised
258 the Roche ECLIA; SF, FR and MT established, conducted and analyzed the DigiWest
259 detection system for SARS-CoV-2 and seasonal CoVs; NR, RB, and MS analyzed the
260 data; NR and MS drafted the figures and wrote the manuscript. MS developed the
261 manuscript to its final form; MS planned and supervised the study; all authors read,
262 edited, and approved the final manuscript.

263

264

265 **Conflict of interest**

266 The authors report no conflict of interest

267

268 **Acknowledgements**

269 We thank all patients and healthy volunteer donors for their cooperation in this study and

270 for their swab specimen collection and blood donation. We thank Thomas Iftner and Tina

271 Ganzenmüller for their support with diagnostic tests and the collection of swab

272 specimens.

273

274 **Funding**

275 This work was supported by grants to MS from the Baden-Württemberg foundation (BW-

276 Stiftung), the Deutsche Forschungsgemeinschaft, the MWK Baden-Württemberg as well

277 as by basic funding provided to MS by the University Hospital Tübingen and TÜFF-

278 Gleichstellungsförderung to K.A. (2563-0-0).

279

280

281

282

283

284

285

286

287

288

289 References

- 290 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from
291 Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-33.
- 292 2. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al.
293 Virological assessment of hospitalized patients with COVID-2019. *Nature*.
294 2020;581(7809):465-9.
- 295 3. Wang C, Horby PW, Hayden FG, and Gao GF. A novel coronavirus outbreak of
296 global health concern. *Lancet*. 2020;395(10223):470-3.
- 297 4. Lai CC, Wang CY, Wang YH, Hsueh SC, Ko WC, and Hsueh PR. Global
298 epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily
299 cumulative index, mortality, and their association with country healthcare
300 resources and economic status. *Int J Antimicrob Agents*. 2020;55(4):105946.
- 301 5. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G,
302 et al. Case characteristics, resource use, and outcomes of 10 021 patients with
303 COVID-19 admitted to 920 German hospitals: an observational study. *Lancet*
304 *Respir Med*. 2020.
- 305 6. Liu X, Liu C, Liu G, Luo W, and Xia N. COVID-19: Progress in diagnostics,
306 therapy and vaccination. *Theranostics*. 2020;10(17):7821-35.
- 307 7. Nicola M, Alsaifi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. The socio-
308 economic implications of the coronavirus pandemic (COVID-19): A review. *Int J*
309 *Surg*. 2020;78:185-93.
- 310 8. Pollan M, Perez-Gomez B, Pastor-Barriuso R, Oteo J, Hernan MA, Perez-Olmeda
311 M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide,
312 population-based seroepidemiological study. *Lancet*. 2020.
- 313 9. Vodicar PM, Valencak AO, Zupan B, Zupanc TA, Kurdija S, Korva M, et al. Low
314 prevalence of active COVID-19 in Slovenia: a nationwide population study on a
315 probability-based sample. *Clin Microbiol Infect*. 2020.
- 316 10. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, and de Lamballerie X.
317 Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French
318 blood donors. *Antiviral Res*. 2020:104880.
- 319 11. Oude Munnink BB, Nieuwenhuijse DF, Stein M, O'Toole A, Haverkate M, Mollers
320 M, et al. Rapid SARS-CoV-2 whole-genome sequencing and analysis for
321 informed public health decision-making in the Netherlands. *Nat Med*. 2020.
- 322 12. Salazar E, Kuchipudi SV, Christensen PA, Eagar T, Yi X, Zhao P, et al.
323 Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor
324 binding domain IgG correlate with virus neutralization. *J Clin Invest*. 2020.
- 325 13. Chen Y, Tong X, Li Y, Gu B, Yan J, Liu Y, et al. A comprehensive, longitudinal
326 analysis of humoral responses specific to four recombinant antigens of SARS-
327 CoV-2 in severe and non-severe COVID-19 patients. *PLoS Pathog*.
328 2020;16(9):e1008796.
- 329 14. Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, Havenar-Daughton C, et
330 al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2.
331 *Nature*. 2020.
- 332 15. Karthik K, Senthilkumar TMA, Udhayavel S, and Raj GD. Role of antibody-
333 dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation
334 strategies for the development of vaccines and immunotherapies to counter
335 COVID-19. *Hum Vaccin Immunother*. 2020:1-6.

- 336 16. Simon F, Ruoff F, Stahl A, Becker M, Kaiser P, Traenkle B, et al. A throughput
337 serological Western blot system using whole virus lysate for the concomitant
338 detection of antibodies against SARS-CoV-2 and human endemic Coronaviridae.
339 *medRxiv*. 2020.
- 340 17. Luchsinger LL, Ransegnola B, Jin D, Muecksch F, Weisblum Y, Bao W, et al.
341 Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody
342 Activity in Recovered COVID19 Patients. *J Clin Microbiol*. 2020.
- 343 18. Sato K, Nagai J, Mitsui N, Ryoko Y, and Takano M. Effects of endocytosis
344 inhibitors on internalization of human IgG by Caco-2 human intestinal epithelial
345 cells. *Life Sci*. 2009;85(23-26):800-7.
- 346 19. Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARS-CoV-
347 2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.
348 *Immunity*. 2020;52(6):971-7 e3.
- 349 20. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al.
350 Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
351 *Nature*. 2020.
- 352 21. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and
353 immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med*.
354 2020.
- 355 22. Xie X, Muruato A, Lokugamage KG, Narayanan K, Zhang X, Zou J, et al. An
356 Infectious cDNA Clone of SARS-CoV-2. *Cell Host Microbe*. 2020;27(5):841-8 e3.
- 357 23. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies
358 elicited by SARS-CoV-2 infection. *Nature*. 2020.
- 359 24. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-
360 CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected
361 controls. *Nature*. 2020.
- 362 25. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-
363 reactive T cells in healthy donors and patients with COVID-19. *Nature*. 2020.
- 364 26. McKechnie JL, and Blish CA. The Innate Immune System: Fighting on the Front
365 Lines or Fanning the Flames of COVID-19? *Cell Host Microbe*. 2020;27(6):863-9.
366

367

368

369

370

371

372

373

374

375

376

377


378

379

380

381

382 **Figures and Table**



384 **Figure 1. Neutralization of SARS-CoV-2 by sera of COVID-19 convalescent**
385 **patients.** (a) Experimental layout of the two neutralization assays employed using the
386 clinical isolate (SARS-CoV-2_Tü1) and the green-fluorescent virus (SARS-CoV-2_mNG).
387 (b) Primary data showing results of both neutralization assays using one patient serum
388 as an example (S28). In the upper row, the total amount of cells for each well of the two-
389 fold serial dilution of sera is shown, as DAPI+/Hoechst+ respectively. In the lower,
390 infected cells are visualized, indicated as Alexa594+/mNG+ cells, respectively. (c)
391 Neutralization curves of five representative sera measured by both assays. The graphs
392 show the nonlinear regression fitting calculated for five patients who displayed different
393 neutralization capacity: no, poor, low, medium, and high neutralization. The VNT₅₀ for
394 each patient are shown next to each curve. (d) Correlation analysis of VNT₅₀ measured
395 by both assays (n=49). (d) Percentage of patients classified according to the VNT₅₀ using
396 SARS-CoV-2_Tü1. The titers used to classify the sera are shown below the columns:
397 <20, 20-200, 201-400, 401-1000 and 1000-2560. Above the columns is shown the
398 percentage of sera that correspond to each category.

399

400

401

402


403

404

405

406

407



408

409

410 **Figure 2. Association of patient characteristics with sera VNT₅₀.** The VNT₅₀ of each
411 patient serum was associated with the individual (a) date of the positive SARS-CoV-2
412 qRT-PCR diagnostic test to blood sampling, (b) the age of the patient, (c) the gender and
413 (d) the number of symptoms reported. Statistical analyses were done with an unpaired
414 two-tailed student's t-test. See detailed patient characteristic in Supplementary Table 1.

415


416

417

418


419

420



421
422 **Figure 3. Correlation of serological parameters with sera VNT₅₀.** The VNT₅₀ of each
423 patient serum was correlated with (a) the value of SARS-CoV-2-S-specific IgGs
424 measured by the Euroimmune ELISA, (b) the relative quantitative value of SARS-CoV-2-
425 S-RBD-specific IgGs measured by the Mediagnost ELISA, (c) the relative quantitative
426 value of SARS-CoV-2-S-RBD-specific IgAs measured by the Mediagnost ELISA, (d) the
427 relative quantitative value of SARS-CoV-2-S-RBD-specific IgMs measured by the
428 Mediagnost ELISA (e) the relative quantitative value of SARS-CoV-2-NC-specific IgGs
429 measured by the Roche ECLIA. Dotted lines indicate the respective assay thresholds

430 defined as positive.



431

432

433 **Figure 4. Correlation of antibodies against seasonal coronaviruses with sera**

434 **VNT₅₀.** The VNT₅₀ of each patient serum was correlated with the relative quantitative

435 value of a throughput diagnostic Western blot detection system measuring CoV-specific

436 IgG against (a) SARS-CoV-2, (b) CoV-229E, (c) CoV-OC43 or (d) CoV-NL64. Dotted

437 lines indicate the respective assay thresholds defined as positive.

438

439

440

441

442

Table 1: Serological parameters of sera and VNT₅₀ values

Patient ID	IgG S	IgG S-RBD	IgG NC	SCoV-2 IgG	VNT50
S11	-	-	-	-	<20
S9	-	-	-	-	<20
S48	-	-	-	-	<20
S2	-	-	-	+	<20
S25	+	+	+	+	20
S47	+		+	+	42,9
S10	+	+	-	+	107,1
S41	+	+	+	+	139,6
S12	+		-	+	143,7
S46	+		-	-	148,5
S7		-	+	+	148,9
S35	+	+	+	+	153,7
S37	+	+	+	+	156,5
S8	+	+	+	+	160,4
S49	+	+	+	+	162,1
S40	+		-	+	164,4
S22	+	+	+	+	208,6
S34	+	+	+	+	218,7
S6	-	-	-	-	219,4
S44	+		+	+	225,2
S1	+	+	-	+	231,8
S26	+	+	+	+	238,2
S21	+	+	+	+	246,9
S32	+	+	+	+	251,2
S29	+	+	+	+	265,8
S45	+	+	+	+	278,1
S24	+	+	+	+	315,5
S30	+	+	+	+	345,3
S38	+		+	+	360,9
S39	+	+	+	+	361,5
S3	+	+	+	+	466
S33	+	+	+	+	489,7
S20	+	+	+	+	490,9
S43	+	+	+	+	521,6
S14	+	+	+	+	542,9
S28	+	+	+	+	579
S42	+	+	+	+	597,7
S27	+	+	+	+	605,7
S17	+	+	+	+	612,7
S36	+	+	+	+	616,1
S18	+	+	+	+	663,6
S5	+	+	+	+	663,6
S4	+	+	+	+	846,7
S31	+	+	+	+	1025
S15	+	+	+	+	1157,1
S19	+	+	+	+	1373,4
S23	+	+	+	+	1447,8
S13	+	+	+	+	2119,5
S16	+	+	+	+	2560
HP_T1	n.a.	+	+	+	2560
HP_T2	n.a.	+	+	+	1454,8
HD1	n.a.	-	-	-	<20
HD2	n.a.	-	-	-	<20
HD3	n.a.	-	-	-	<20
HD4	n.a.	-	-	-	<20

Sera of the 49 patients are ordered by their VNT₅₀ and colour-coded. For the serological tests indicated there is a qualitative indicator for a value above the threshold (+), below the threshold (-) or borderline (0) for the respective assay. At the bottom of the table the control sera are shown. Two consecutive sera of a hospitalized patient (HP_T1/T2) and four sera of healthy donors (HD1-4). All the individual values and the specific patient characteristics are listed in Supplementary Table 1.

444 **Methods**

445 **Study participants and sample processing.** Blood was drawn from potential blood
446 donors for convalescent plasma therapy after written consent at the Clinical
447 Transfusion Medicine, Tübingen between April 04 and May 12, 2020, under the
448 guidelines of the local ethics committees 222/2020BO. All patients (n=49) were older
449 than 18 years old and provided a PCR-confirmed diagnosis of SARS-CoV-2 (n=46) and
450 three were symptomatic and close contacts to positively diagnosed COVID-19 patients
451 (partners tested positive). All patients were non-hospitalized with asymptomatic to mild
452 courses of disease and they were fully convalescent showing no symptoms on the day
453 of blood donation. Basic demographic information was collected including age and sex,
454 as well as self-perceived symptoms (cough, fever, limb pain and headache, diarrhea,
455 and loss of taste). In addition, blood from four healthy donors and one hospitalized
456 patient was collected (Supplementary Table 1). Serum samples were stored at -80°C.

457 **Cell culture.** Caco-2 (Human Colorectal adenocarcinoma) cells were cultured at 37 °C
458 with 5% CO₂ in DMEM containing 10% FCS, with 2 mM l-glutamine, 100 µg/ml penicillin-
459 streptomycin and 1% NEAA.

460 **Viruses.** A throat swab sample collected in March 2020 at the diagnostic department of
461 the Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital
462 Tübingen, from a SARS-CoV-2 positive patient was used to isolate the virus
463 (200325_Tü1). 50 µl of patient material was diluted in media, sterile-filtrated, and used
464 directly to inoculate 200.000 Caco-2 cells in a 6-well. 48 hpi (hours post-infection) the
465 supernatant was collected, centrifuged, and stored at -80°C. Supernatant as well as cell
466 lysates from infected cells were tested by Western blot using a SARS-CoV-2 anti-
467 nucleocapsid protein (NP) specific antibody (GeneTex). In addition, the identity of the

468 virus was confirmed by qRT-PCR diagnostics via S and E gene amplification. An aliquot
469 of the isolate was used to amplify the virus in a medium flask of Caco-2 cells (2×10^6
470 cells) in 13 ml DMEM + supplements and 5% FCS. 48 hpi, the supernatant was
471 centrifuged and stored in aliquots at -80°C .

472 The recombinant SARS-CoV-2 expressing mNeonGreen (icSARS-CoV-2-mNG) (22) was
473 obtained from the World Reference Center for Emerging Viruses and Arboviruses
474 (WRCEVA) at the UTMB (University of Texas Medical Branch). To generate icSARS-
475 CoV-2-mNG stocks, Caco-2 cells were infected as above, the supernatant was
476 harvested 48 hpi, centrifuged, and stored at -80°C .

477 For MOI determination, a titration using serial dilutions of both virus stocks (200325_Tü1
478 and mNG) was conducted. The number of infectious virus particles per ml was calculated
479 as the $(\text{MOI} \times \text{cell number}) / (\text{infection volume})$, where $\text{MOI} = -\ln(1 - \text{infection rate})$. To
480 reach an infection rate of ~20% an MOI of 0.3 was used for SARS-CoV-2-200325_Tü1
481 and 1.1 for SARS-CoV-2.mNG.

482 **Enzyme-linked Immunosorbent Assays (ELISAs); Euroimmun**, the Euroimmun
483 SARS-CoV-2-ELISA (IgG) (Euroimmun, Lübeck, Germany) with the recombinant S1
484 target antigen of SARS-CoV-2 was performed according to manufacturer's instructions in
485 serum. Patient samples are diluted 1:101 in sample buffer. The included controls and
486 calibrator in the test kit were used with each run. Results are given as ratios (optical
487 density (OD) of control or clinical sample/OD of calibrator). According to the
488 manufacture, ratios were classified as negative (< 0.8), borderline ($\geq 0.8 - < 1.1$) and
489 positive (≥ 1.1). **Mediagnost**, IgG antibody detection directed to the S1 RBD SARS-CoV-
490 2 in human sera using Mediagnost test system was made according to the
491 manufacturer's instructions. Briefly, these tests are two-step enzyme-linked

492 immunosorbent assays. The solid phase consists of a 96-well Microtiter plate (Greiner,
493 Bio-One, Frickenhausen Germany) that is coated with the recombinant SARS-CoV-2
494 spike protein S1. The antibodies from patients that are directed against SARS-CoV-2 S1
495 protein bind to the solid phase coated S1 protein. Next a horseradish peroxidase (HRP)
496 conjugated goat anti-human IgG binds to the human IgG antibodies. The following step
497 involves the substrate for the HRP being added by which the substrate is converted from
498 colorless into blue color; and after addition of a stop solution the color changes to yellow.
499 The extinction of the yellow solution can be measured at a wavelength at 450 nm with
500 reference at 620 nm. Increasing extinctions represent increasing amounts of antibodies
501 to SARS-CoV-2 S1 protein. Samples showing extinctions that were three times higher
502 than the negative control can be interpreted as being positive for anti- SARS-CoV-2 S1.
503 IgA and IgM antibody detection directed to the SARS-CoV-2 S1 protein was made in
504 analogy to the above-described IgG detection system except that the HRP labeled
505 detection antibody was directed against human IgA or human IgM antibodies. According
506 to the manufacture, ratios were classified as negative ($<0,42$), borderline ($\geq 0,42-0,7$) and
507 positive ($\geq 0,7$) for IgG, ($<0,33$), ($\geq 0,33-0,7$) and ($\geq 0,7$) for IgA and ($<0,87$), ($\geq 0,87-1,47$)
508 and ($\geq 1,47$) for IgM.

509 **Elecsys anti-SARS-CoV-2 (Roche).** For qualitative detection of anti SARS-CoV-2
510 (IgG+IgM) antibodies the electrochemiluminescence immunoassay (ECLIA) was
511 performed using the fully automated cobas e 6000/601 immunoassay analyzer (Roche
512 Diagnostics, Mannheim, Germany). This assay targets recombinant SARS-CoV-2
513 nucleocapsid (NC) protein. Two calibrators are used (Cal1 nonreactive, COI 0,101; and
514 Cal2 reactive, COI 1,2) in the double antigen-sandwich based assay (SARS-CoV -2
515 recNC biotin label, and SARS-CoV-2 recNC ruthenium complex label). Each, 20 μ l of

516 sera and reference solutions were used, immune complexes are fixed to streptavidin-
517 coated microparticles. Read out is given in relative light units in the form of cutoff index
518 (COI, signal/cutoff). The Elecsys reagents derived from LOT 49500101. For negative
519 control (<150% Cal1), we used pooled sera from 100 mothers at birth of the Tuebingen
520 congenital CMV study 2012. Furthermore, we used a negative control serum from a
521 direct Covid-19 contact person, repeatedly negative tested for SARS-CoV-2 RNA and
522 nucleocapsid-specific antibodies without any symptoms during and after a one week
523 close exposition. For positive control, we used a dilution series of a serum from a
524 reconvalescent student infected symptomatically (fever, cough, loss of smell) tested
525 positive for viral RNA and NC-specific antibodies. The COIs ranged from 100 to 1. If the
526 numeric COI result was $\geq 1,0$, the serum was diagnosed as reactive, COI <1,0 were
527 attributed as non-reactive. COI values of the positive controls were stable over at least 2
528 months.

529 **Multiplexed detection of anti-coronavirus antibodies.** Whole viral protein lysates from
530 229E, OC43, and NL63 (ZeptoMetrix Corp) and from SARS-CoV-2 were used for
531 DigiWest as described (16). Viral protein lysates were used for denaturing gel
532 electrophoresis and Western blotting using the NuPAGE system. Blot membranes were
533 washed with PBST (0.1% Tween-20, PBS) and membrane-bound proteins were
534 biotinylated by adding 50 μ M NHS-PEG12-Biotin (Thermo Fisher Scientific) in PBST for
535 1 h. After washing in PBST, membranes were dried overnight. Subsequently, the
536 Western-Blot lanes were cut into 96 strips of 0.5 mm width and were transferred to a 96-
537 well plate (Greiner Bio-One). For protein elution, 10 μ L of elution buffer was added to
538 each well (8 M urea, 1% Triton-X100 in 100 mM Tris-HCl pH 9.5). The protein eluates
539 were diluted with 90 μ L dilution buffer (5% BSA in PBST, 0.02% sodium azide).

540 Neutravidin-coated MagPlex beads (Luminex) of a distinct colour ID were added to the
541 protein eluates and binding was allowed overnight; 500 μ M PEG12-biotin in PBST was
542 added to block remaining Neutravidin binding sites. The bead containing fractions were
543 pooled and thereby the original Western blot lanes were reconstituted. Beads were
544 washed in PBST and resuspended in store buffer (1% BSA, 0.05 % azide, PBS). The
545 generated bead-set represents the proteomes of the four coronaviruses (SARS-CoV-2,
546 OC43, 229E, NL63) and reactivity against all proteins can be tested in one assay.

547 For serum incubation, 5 μ L of the bead mix were equilibrated in 50 μ L serum assay
548 buffer (Blocking Reagent for ELISA (Roche) supplemented with 0.2% milk powder,
549 0.05% Tween-20 and 0.02% sodium azide, 25% Low Cross buffer (Candor Bioscience),
550 25% IgM-reducing agent buffer (ImmunoChemistry). Serum assay buffer was discarded
551 and 30 μ L of diluted patient serum (1:200 in serum assay buffer) was added and
552 incubated for 2 hours at RT on a shaker. After washing in PBST, 30 μ L of Phycoerythrin
553 labelled anti-human IgG secondary antibody (diluted 1:200 in serum assay buffer;
554 Dianova) was added and incubated for 45 min at 23 °C. The beads were washed twice
555 with PBST and readout was performed on a Luminex FlexMAP 3D.

556 The DigiWest analysis tool was used to assess serum reactivity against the viral proteins
557 (16). Virus protein-specific peaks were identified and average fluorescence intensity
558 (AFI) values were calculated by integration of peak areas.

559 **Neutralization assay.** For neutralization experiments, 1×10^4 Caco-2 cells/well were
560 seeded in 96-well plates the day before infection in media containing 5% FCS. Cells
561 were co-incubated with SARS-CoV-2 clinical isolate 200325_Tü1 at a MOI=0.3 and
562 patient sera in serial two-fold dilutions from 1:20 up to 1:2560. 48 hpi cells were fixed
563 with 80% acetone for 5 minutes, washed with PBS, and blocked for 30 minutes at room

564 temperature (rt) with 10 % normal goat serum (NGS). Cells were incubated for 1 h at rt
565 with 100 μ l of serum from a hospitalized convalescent donor in a 1:1000 dilution and
566 washed 3 times with PBS. 100 μ l of goat anti-human Alexa594 1:2000 in PBS was used
567 as secondary antibody for 1h at rt. Cells were washed 3 times with PBS and counter-
568 stained with 1:20000 DAPI solution (2 mg/ml) for 10 minutes at rt. For quantification of
569 infection rates images were taken with the Cytation3 (Biotek) and DAPI+ and Alexa594+
570 cells were automatically counted by the Gen5 Software (Biotek).

571 Alternatively, Caco-2 cells were co-incubated with the SARS-CoV-2 strain icSARS-CoV-
572 2-mNG at a MOI=1.1 and patient sera in serial two-fold dilutions from 1:40 up to 1:5120.
573 48 hpi cells were fixed with 2% PFA and stained with Hoechst33342 (1 μ g/mL final
574 concentration) for 10 minutes at 37°C. The staining solution was removed and
575 exchanged for PBS. For quantification of infection rates images were taken with the
576 Cytation3 (Biotek) and Hoechst+ and mNG+ cells were automatically counted by the
577 Gen5 Software (Biotek). Virus neutralizing titers (VNT₅₀) were calculated as the half-
578 maximal inhibitory dose (ID₅₀) using 4-parameter nonlinear regression (GraphPad
579 Prism).

580 **Software and statistical analysis.** GraphPad Prism 8.0 was used for statistical and
581 correlation analyses and to generate graphs. Figures were generated with CorelDrawX7.
582 Other software used included Gen5 v.3.04.

583